Study Overview: This study is for people with newly diagnosed acute myeloid leukemia (AML) that have a specific change in their IDH2 gene. The study is testing if adding the medicine enasidenib can improve treatment. Enasidenib helps stop cancer cells with the IDH2 mutation from growing. The study compares two groups: one group takes ASTX727 (a combination of decitabine and cedazuridine) and venetoclax, and the other group takes ASTX727, venetoclax, plus enasidenib.

Key Points:

• The study lasts up to 5 years, with follow-up visits every few months.
• Participants must have AML with the IDH2 mutation and meet specific health criteria.
• Potential side effects and safety are closely monitored throughout the study.

Participation Requirements: Participants should be 60 years or older, or at least 18 if they cannot receive standard treatment. They must not have received prior treatment for AML except for certain allowed medicines. The study involves taking oral medicines and regular health check-ups, including blood and bone marrow tests. Participation includes agreeing to provide samples for research and following study procedures. Interested individuals should discuss with their doctor if this study may be suitable for them.